Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental drug karonudib tested in patients with no other options

NCT ID NCT04077307

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 26 times

Summary

This early-phase study tests the safety and tolerability of a new drug called Karonudib in adults with blood cancers like leukemia who have exhausted standard treatments. The goal is to find a safe dose and look for early signs that the drug might help control the disease. Only 9 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Aarhus University Hospital

    RECRUITING

    Aarhus, Denmark

    Contact

  • Karolinska University Hospital

    RECRUITING

    Huddinge, Sweden

    Contact

    Contact

  • Rigshospitalet Copenhagen University Hospital

    RECRUITING

    Copenhagen, Denmark

    Contact

  • University Clinical Center Belgrade

    RECRUITING

    Belgrade, Serbia

    Contact

  • University Clinical Center Kragujevac

    RECRUITING

    Kragujevac, Serbia

    Contact

  • Örebro University Hospital

    RECRUITING

    Örebro, Sweden

    Contact

Conditions

Explore the condition pages connected to this study.